(NASDAQ: PRLD) Prelude Therapeutics's forecast annual revenue growth rate of 56.17% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.51%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.32%.
Prelude Therapeutics's revenue in 2026 is $22,424,000.On average, 6 Wall Street analysts forecast PRLD's revenue for 2026 to be $3,512,071,571, with the lowest PRLD revenue forecast at $1,564,148,306, and the highest PRLD revenue forecast at $9,242,839,633. On average, 6 Wall Street analysts forecast PRLD's revenue for 2027 to be $2,956,878,726, with the lowest PRLD revenue forecast at $938,488,984, and the highest PRLD revenue forecast at $8,379,365,925.
In 2028, PRLD is forecast to generate $8,139,955,470 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $16,758,731,850.